Leonard W.F. Seelen MD, Lieke van den Wildenberg MS, Ayhan Gursan MS, Martijn Froeling PhD, Mark W.J.M. Gosselink MS, Wybe J.M. van der Kemp PhD, Nadia Haj Mohammad MD, PhD, I. Quintus Molenaar MD, PhD, Hjalmar C. van Santvoort MD, PhD, Dennis W.J. Klomp PhD, Jeanine J. Prompers PhD
{"title":"胰腺中的 31 P MR 光谱：重复性、与肝脏的比较以及胰腺癌试验数据。","authors":"Leonard W.F. Seelen MD, Lieke van den Wildenberg MS, Ayhan Gursan MS, Martijn Froeling PhD, Mark W.J.M. Gosselink MS, Wybe J.M. van der Kemp PhD, Nadia Haj Mohammad MD, PhD, I. Quintus Molenaar MD, PhD, Hjalmar C. van Santvoort MD, PhD, Dennis W.J. Klomp PhD, Jeanine J. Prompers PhD","doi":"10.1002/jmri.29326","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>Non-invasive evaluation of phosphomonoesters (PMEs) and phosphodiesters (PDEs) by 31-phosphorus MR spectroscopy (<sup>31</sup>P MRS) may have potential for early therapy (non-)response assessment in cancer. However, <sup>31</sup>P MRS has not yet been applied to investigate the human pancreas <i>in vivo</i>.</p>\n </section>\n \n <section>\n \n <h3> Purpose</h3>\n \n <p>To assess the technical feasibility and repeatability of <sup>31</sup>P MR spectroscopic imaging (MRSI) of the pancreas, compare <sup>31</sup>P metabolite levels between pancreas and liver, and determine the feasibility of <sup>31</sup>P MRSI in pancreatic cancer.</p>\n </section>\n \n <section>\n \n <h3> Study Type</h3>\n \n <p>Prospective cohort study.</p>\n </section>\n \n <section>\n \n <h3> Population</h3>\n \n <p>10 healthy subjects (age 34 ± 12 years, four females) and one patient (73-year-old female) with pancreatic ductal adenocarcinoma.</p>\n </section>\n \n <section>\n \n <h3> Field Strength/Sequence</h3>\n \n <p>7-T, <sup>31</sup>P FID-MRSI, <sup>1</sup>H gradient-echo MRI.</p>\n </section>\n \n <section>\n \n <h3> Assessment</h3>\n \n <p><sup>31</sup>P FID-MRSI of the abdomen (including the pancreas and liver) was performed with a nominal voxel size of 20 mm (isotropic). For repeatability measurements, healthy subjects were scanned twice on the same day. The patient was only scanned once. Test–retest <sup>31</sup>P MRSI data of pancreas and liver voxels (segmented on <sup>1</sup>H MRI) of healthy subjects were quantified by fitting in the time domain and signal amplitudes were normalized to γ-adenosine triphosphate. In addition, the PME/PDE ratio was calculated. Metabolite levels were averaged over all voxels within the pancreas, right liver lobe and left liver lobe, respectively.</p>\n </section>\n \n <section>\n \n <h3> Statistical Tests</h3>\n \n <p>Repeatability of test–retest data from healthy pancreas was assessed by paired <i>t</i>-tests, Bland–Altman analyses, and calculation of the intrasubject coefficients of variation (CoVs). Significant differences between healthy pancreas and right and left liver lobes were assessed with a two-way analysis of variance (ANOVA) for repeated measures. A <i>P</i>-value <0.05 was considered statistically significant.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The intrasubject CoVs for PME, PDE, and PME/PDE in healthy pancreas were below 20%. Furthermore, PME and PME/PDE were significantly higher in pancreas compared to liver. In the patient with pancreatic cancer, qualitatively, elevated relative PME signals were observed in comparison with healthy pancreas.</p>\n </section>\n \n <section>\n \n <h3> Data Conclusion</h3>\n \n <p><i>In vivo</i> <sup>31</sup>P MRSI of the human healthy pancreas and in pancreatic cancer may be feasible at 7 T.</p>\n </section>\n \n <section>\n \n <h3> Evidence Level</h3>\n \n <p>3</p>\n </section>\n \n <section>\n \n <h3> Technical Efficacy</h3>\n \n <p>Stage 2</p>\n </section>\n </div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmri.29326","citationCount":"0","resultStr":"{\"title\":\"31P MR Spectroscopy in the Pancreas: Repeatability, Comparison With Liver, and Pilot Pancreatic Cancer Data\",\"authors\":\"Leonard W.F. Seelen MD, Lieke van den Wildenberg MS, Ayhan Gursan MS, Martijn Froeling PhD, Mark W.J.M. Gosselink MS, Wybe J.M. van der Kemp PhD, Nadia Haj Mohammad MD, PhD, I. Quintus Molenaar MD, PhD, Hjalmar C. van Santvoort MD, PhD, Dennis W.J. Klomp PhD, Jeanine J. Prompers PhD\",\"doi\":\"10.1002/jmri.29326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Non-invasive evaluation of phosphomonoesters (PMEs) and phosphodiesters (PDEs) by 31-phosphorus MR spectroscopy (<sup>31</sup>P MRS) may have potential for early therapy (non-)response assessment in cancer. However, <sup>31</sup>P MRS has not yet been applied to investigate the human pancreas <i>in vivo</i>.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Purpose</h3>\\n \\n <p>To assess the technical feasibility and repeatability of <sup>31</sup>P MR spectroscopic imaging (MRSI) of the pancreas, compare <sup>31</sup>P metabolite levels between pancreas and liver, and determine the feasibility of <sup>31</sup>P MRSI in pancreatic cancer.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Study Type</h3>\\n \\n <p>Prospective cohort study.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Population</h3>\\n \\n <p>10 healthy subjects (age 34 ± 12 years, four females) and one patient (73-year-old female) with pancreatic ductal adenocarcinoma.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Field Strength/Sequence</h3>\\n \\n <p>7-T, <sup>31</sup>P FID-MRSI, <sup>1</sup>H gradient-echo MRI.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Assessment</h3>\\n \\n <p><sup>31</sup>P FID-MRSI of the abdomen (including the pancreas and liver) was performed with a nominal voxel size of 20 mm (isotropic). For repeatability measurements, healthy subjects were scanned twice on the same day. The patient was only scanned once. Test–retest <sup>31</sup>P MRSI data of pancreas and liver voxels (segmented on <sup>1</sup>H MRI) of healthy subjects were quantified by fitting in the time domain and signal amplitudes were normalized to γ-adenosine triphosphate. In addition, the PME/PDE ratio was calculated. Metabolite levels were averaged over all voxels within the pancreas, right liver lobe and left liver lobe, respectively.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Statistical Tests</h3>\\n \\n <p>Repeatability of test–retest data from healthy pancreas was assessed by paired <i>t</i>-tests, Bland–Altman analyses, and calculation of the intrasubject coefficients of variation (CoVs). Significant differences between healthy pancreas and right and left liver lobes were assessed with a two-way analysis of variance (ANOVA) for repeated measures. A <i>P</i>-value <0.05 was considered statistically significant.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The intrasubject CoVs for PME, PDE, and PME/PDE in healthy pancreas were below 20%. Furthermore, PME and PME/PDE were significantly higher in pancreas compared to liver. In the patient with pancreatic cancer, qualitatively, elevated relative PME signals were observed in comparison with healthy pancreas.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Data Conclusion</h3>\\n \\n <p><i>In vivo</i> <sup>31</sup>P MRSI of the human healthy pancreas and in pancreatic cancer may be feasible at 7 T.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Evidence Level</h3>\\n \\n <p>3</p>\\n </section>\\n \\n <section>\\n \\n <h3> Technical Efficacy</h3>\\n \\n <p>Stage 2</p>\\n </section>\\n </div>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmri.29326\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jmri.29326\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jmri.29326","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
摘要
背景：通过31-磷磁共振波谱（31 P MRS）对磷单酯（PMEs）和磷二酯（PDEs）进行非侵入性评估，可用于癌症早期治疗（非）反应评估。目的：评估胰腺 31 P MR 光谱成像（MRSI）的技术可行性和可重复性，比较胰腺和肝脏的 31 P 代谢物水平，并确定 31 P MRSI 在胰腺癌中的可行性：研究类型：前瞻性队列研究：10 名健康受试者（年龄 34 ± 12 岁，4 名女性）和 1 名胰腺导管腺癌患者（73 岁，女性）：7-T、31 P FID-MRSI、1 H 梯度回波磁共振成像：对腹部（包括胰腺和肝脏）进行了 31 P FID-MRSI，标称体素大小为 20 毫米（各向同性）。为了测量重复性，健康受试者在同一天接受了两次扫描。患者只扫描一次。健康受试者胰腺和肝脏体素（在 1 H MRI 上分割）的测试-重复 31 P MRSI 数据通过时域拟合进行量化，信号振幅归一化为γ-三磷酸腺苷。此外，还计算了 PME/PDE 比率。代谢物水平分别取胰腺、右肝叶和左肝叶所有体素的平均值：通过配对 t 检验、Bland-Altman 分析和计算受试者内变异系数 (CoVs) 来评估健康胰腺测试-重复测试数据的可重复性。健康胰腺与左右肝叶之间的显著差异通过重复测量的双向方差分析（ANOVA）进行评估。A P值结果：健康胰腺中 PME、PDE 和 PME/PDE 的受试者内 CoV 值低于 20%。此外，胰腺中的 PME 和 PME/PDE 明显高于肝脏。与健康胰腺相比，在胰腺癌患者体内观察到的相对 PME 信号定性升高：数据结论：在 7 T 下对人体健康胰腺和胰腺癌进行体内 31 P MRSI 可能是可行的。
31P MR Spectroscopy in the Pancreas: Repeatability, Comparison With Liver, and Pilot Pancreatic Cancer Data
Background
Non-invasive evaluation of phosphomonoesters (PMEs) and phosphodiesters (PDEs) by 31-phosphorus MR spectroscopy (31P MRS) may have potential for early therapy (non-)response assessment in cancer. However, 31P MRS has not yet been applied to investigate the human pancreas in vivo.
Purpose
To assess the technical feasibility and repeatability of 31P MR spectroscopic imaging (MRSI) of the pancreas, compare 31P metabolite levels between pancreas and liver, and determine the feasibility of 31P MRSI in pancreatic cancer.
Study Type
Prospective cohort study.
Population
10 healthy subjects (age 34 ± 12 years, four females) and one patient (73-year-old female) with pancreatic ductal adenocarcinoma.
Field Strength/Sequence
7-T, 31P FID-MRSI, 1H gradient-echo MRI.
Assessment
31P FID-MRSI of the abdomen (including the pancreas and liver) was performed with a nominal voxel size of 20 mm (isotropic). For repeatability measurements, healthy subjects were scanned twice on the same day. The patient was only scanned once. Test–retest 31P MRSI data of pancreas and liver voxels (segmented on 1H MRI) of healthy subjects were quantified by fitting in the time domain and signal amplitudes were normalized to γ-adenosine triphosphate. In addition, the PME/PDE ratio was calculated. Metabolite levels were averaged over all voxels within the pancreas, right liver lobe and left liver lobe, respectively.
Statistical Tests
Repeatability of test–retest data from healthy pancreas was assessed by paired t-tests, Bland–Altman analyses, and calculation of the intrasubject coefficients of variation (CoVs). Significant differences between healthy pancreas and right and left liver lobes were assessed with a two-way analysis of variance (ANOVA) for repeated measures. A P-value <0.05 was considered statistically significant.
Results
The intrasubject CoVs for PME, PDE, and PME/PDE in healthy pancreas were below 20%. Furthermore, PME and PME/PDE were significantly higher in pancreas compared to liver. In the patient with pancreatic cancer, qualitatively, elevated relative PME signals were observed in comparison with healthy pancreas.
Data Conclusion
In vivo31P MRSI of the human healthy pancreas and in pancreatic cancer may be feasible at 7 T.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
